CHU de Bordeaux
Bordeaux, France
NCT Number: NCT04657419
Recent studies show that patients who have contracted COVID-19 retain very significant fatigue after resolving the infectious episode. This fatigue may be explained by low-grade inflammation. There is more data for patients with COVID-19 who have been hospitalized than for non-hospitalized patients with milder forms.
However, COVID-19 related fatigue would not only affect elderly people with severe cardiopulmonary consequences but also young subjects without severities. This notion is not very widespread and to date, COVID contracted by young subjects is considered to have very few consequences on their health.
It is also known that the prevalence of sleep debt is significant in the general population and particularly in young people, and it is also known that sleep deprivation increases low-grade inflammation and facilitates the risk of viral contamination. The association between sleep deprivation, drowsiness and possibly low-grade inflammation raise questions about the mechanisms of fatigue in the general population.
Investigators are also entitled to wonder to what extent the chronic sleep debt suffered by the French population can explain an increased risk of contamination by COVID 19 but also significant residual fatigue after COVID infection.
Bordeaux University Hospital screens 2,000 subjects per day at risk of being infected by COVID, it would be very interesting to measure, in a population of young adults aged 18-45 years, frequently exposed to a sleep debt, sleep hygiene (bedtime and wake-up times, sleep and wake-up schedules, and overall sleep satisfaction), average sleep duration, level of fatigue and drowsiness and to compare these thresholds between subjects with or without COVID 19 according to nasopharyngeal PCR.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Observational
Bordeaux, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Self-questionnaires will be completed by the participants :
Time frame: one month after inclusion (T0)
Presence of significant fatigue as measured by the Fatigue Severity Scale (FSS) at 1 month.
Score from 1 to 7 FSS is a 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale.
The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree.
The minimum score is 9 and maximum score possible is 63. Higher is the score, greater is the fatigue severity
Time frame: inclusion (T0)
Diagnosis of COVID-19 by nasopharyngeal PCR
Time frame: Inclusion (T0) and one month after
Fatigue measured by Fatigue Severity Scale FSS is a 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale.
The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree.
The minimum score is 9 and maximum score possible is 63. Higher is the score, greater is the fatigue severity
Time frame: Inclusion (T0) and one month after
Sleep hygiene measured with questionnaire
University Hospital, Bordeaux
Other
Acronym: COFATSOM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04860869
COVID-19, Cognition Disorders
Galveston, Texas, United States
View Trial DetailsNCT05027724
Autonomic Nervous System Diseases, COVID-19
Dublin, Co. Dublin, Ireland
View Trial DetailsNCT04980573
COVID-19, Coronaviridae Infections
Franklin, Tennessee, United States
View Trial DetailsNCT04795557
Anxiety Disorders, Behavior
Tbilisi, Georgia
View Trial Details